Progressive multifocal leukoencephalopathy after natalizumab discontinuation
Andrew J Fine1, Alfred Sorbello, Cindy Kortepeter
1Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
Patients discontinuing natalizumab (NTZ) for multiple sclerosis (MS) can develop progressive multifocal leukoencephalopathy (PML) within six months. Many cases have pre-existing PML risk factors, requiring clinician awareness.
Area of Science:
- Neurology
- Immunology
Background:
- Natalizumab (NTZ) is an effective treatment for multiple sclerosis (MS).
- Discontinuation of NTZ can be followed by opportunistic infections, including progressive multifocal leukoencephalopathy (PML).
Purpose of the Study:
- To identify cases of laboratory- or biopsy-confirmed progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS) who previously discontinued natalizumab (NTZ) for reasons unrelated to suspected or proven PML.
- To assess PML risk factors in these identified cases.
Main Methods:
- Searched US Food and Drug Administration Adverse Event Reporting System and MEDLINE for reports from 2006-2012.
- Included laboratory-confirmed PML cases with symptom onset ≥30 days post-NTZ withdrawal, where discontinuation was unrelated to suspected PML.
Main Results:
- Identified 17 patients with PML after NTZ discontinuation for non-PML reasons; median NTZ duration was 47 doses.
- PML was confirmed within 6 months of withdrawal; 11 patients experienced immune reconstitution inflammatory syndrome (IRIS).
- At NTZ withdrawal, 94% had ≥1 PML risk factor, including NTZ duration ≥2 years (n=13), prior immunosuppressants (n=8), and anti-JC virus seropositivity (n=13).
Conclusions:
- Patients discontinuing NTZ for MS may develop PML within 6 months, often with pre-existing risk factors.
- Heightened clinical awareness for PML, IRIS, and MS relapse is crucial when evaluating neurological decline post-NTZ discontinuation.
More Related Videos
26:48Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
Related Concept Videos
Encephalitis l: Introduction
Multiple Sclerosis l: Introduction
Encephalitis ll: Pathophysiology
Arboviral Encephalitis
Hepatic Encephalopathy
Antiepileptic Drugs: Glutamate Antagonists
